Obligations of Foreign Manufacturers in Canada

1. Key takeaways

A foreign manufacturer entering Canada must discharge six obligations: first, the classification determination; second, obtaining an MDL for Class II, III, and IV devices; third, holding a valid MDSAP certificate covering Canada in the audit scope, mandatory since 2019-01-01; fourth, labelling and instructions for use compliant with the language requirements of section 23; fifth, mandatory adverse event reporting under sections 59 to 61; and sixth, recalls and corrective actions under sections 63.2, 64, and 65. In addition, the manufacturer must designate or work with a Canadian importer or distributor to complete the MDEL arrangement on the import side.

• Foreign status brings no relief from obligations in Canada, and the structure differs from the United States agent model.
• Sale or import of a Class II, III, or IV device without a valid MDL is prohibited by the official rule.
• MDSAP is the substantive gate for foreign manufacturers of Class II to IV devices.
• The six obligations form a series, so a break at any node interrupts the whole supply chain.

2. Legal basis

The table below lists the instruments relied upon in this article, together with the relevant provisions, dates, and official sources.

3. Expert insights

Insight one: foreign status does not reduce obligations, but the structure differs from that of the United States.

The United States requires a foreign production company to appoint a United States Agent in addition to its other duties. Canada has no statutory role of agent at all. The responsibilities of a foreign manufacturer are carried by its own MDL, and the compliance of the import and distribution links is carried by the Canadian importer or distributor holding an MDEL. This is the largest structural difference between the two markets, and a company that plans its Canadian entry around the American agent model will misplace where its duties fall, since in Canada the licence burden rests on the manufacturer itself rather than on a local representative.

Insight two: the rule that sale or import is prohibited without a valid MDL is an official formulation.

The official Health Canada page states: “Class II, III or IV medical devices cannot be sold or imported in Canada without a valid medical device licence (MDL).” The word valid carries real weight: it means that when a licence is suspended or cancelled, the authority to sell ends with it. Commercial plans should therefore treat licence validity as a live status to be monitored, because the permission to sell is not a one-time grant but a standing condition that must hold on the day of each sale and each importation.

Insight three: MDSAP is the substantive gate for foreign manufacturers (practical estimate).

MDSAP became the audit program recognized in Canada from 2019-01-01, replacing the former CMDCAS, the Canadian Medical Devices Conformity Assessment System, which operated from 1998 to 2018. Manufacturers of Class II to Class IV devices must hold a valid MDSAP certificate in order to obtain or maintain an MDL. The confirmation standard for this date and for the replacement relationship is the official Health Canada announcement; this paragraph is a practical estimate compilation and readers are directed to the note at the end for the verification basis.

Insight four: the six obligations form a series.

Without an MDSAP certificate, the MDL application is not accepted. Without an MDL, Class II to IV devices cannot be imported. Without an importer holding an MDEL, the import link lacks a compliant entity. Without incident reporting and recall procedures, the post-market obligations have no carrier. Each node depends on the one before it, and a failure at any single point stops the supply chain. Managing the obligations as a connected sequence, rather than as a flat checklist, is what keeps the chain intact. Each node also has its own evidence trail, so the file for the project should show the certificate, the licence, the signed import agreement, and the live procedures as four separately verifiable artifacts rather than one blended package.

4. Practical recommendations

• Manage the six obligations with a series diagram rather than a parallel list, and monitor the MDSAP node and the MDL node, which sit upstream of everything else.
• Schedule the MDSAP certification period and the MDL application period in parallel, not one after the other.
• Prepare the foreign production site as if an inspection could arrive at any time: distribution records, complaint handling, incident reporting, and recall procedure documents must be retrievable on demand.
• Divide the submission responsibilities for incident reporting and recalls with the Canadian importer in the agreement; the importer may be authorized to submit on the manufacturer’s behalf under section 65.1.
• Assign the six obligations to one responsible person and one annual calendar.

5. Verification checklist

• □ The classification determination is complete
• □ For Class II to IV devices, the MDL has been obtained (or submitted, with the status still active)
• □ A valid MDSAP certificate is held, with Canada included in the audit scope
• □ Labels and instructions for use comply with sections 21 to 23
• □ The adverse event reporting process (10 days / 30 days) is live
• □ The recall process (24-hour notification) is live
• □ The MDEL status of the Canadian importer or distributor has been verified

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com